Headquartered in Denver, CO Fiscal year ends December NASDAQ: PALI palisadebio.com
Palisade Bio, Inc. (Nasdaq: PALI) is a clinical-stage biopharmaceutical company developing prodrugs for patients living with inflammatory and fibrotic diseases. The company's lead clinical product candidate, PALI-2108, is a once-daily oral, locally-activated PDE4 inhibitor prodrug specifically engineered for the treatment of inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD). PALI-2108 is designed for targeted activation within the gastrointestinal tract, aiming to deliver sustained PDE4 inhibition while improving tolerability and convenience compared to existing therapies. The company has completed a Phase 1 clinical trial and is advancing into Phase 2 development with two planned trials: ASCENTRA-UC for ulcerative colitis and ASCENTRA-CD for Crohn's disease. Palisade Bio also has a co-development and distribution agreement with Newsoara, a joint venture established by Biolead Medical Technology Limited. The company trades on Nasdaq under the ticker PALI. Updated
Pre-Market Stock Futures: The futures are trading lower as we begin the final trading week of 2025, albeit a holiday-shortened one once again. The major indices all finished the session modestly lower…
Palisade Bio, Inc. (Nasdaq: PALI) is a clinical-stage biopharmaceutical company developing prodrugs for patients living with inflammatory and fibrotic diseases.
The Wall Street consensus 12-month price target for PALI is $9.80.
